276 completed, 68 unknown, 31 recruiting, 19 terminated. 137 Not applicable, 87 Phase 3, 71 Phase 2, 52 Phase 4, 40 Phase 1.
Follow Vaginitis: new trials by email Literature Review of Vaginitis trials Research Report on Vaginitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment metronidazole (MTZ)+ LCFA-01 placebo + LC103 placebo, metronidazole (MTZ)+ LCFA-01 + LC103 placebo, metronidazole (MTZ)+ LC103 + LCFA-01 placebo - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Massachusetts General Hospital | 280 | 2027-02-03 | 2026-10-15 |
| Prevention of Vaginal Cuff Infection After Hysterectomy by Addition of Vaginal Clindamycin Clindamycin Vaginal Gel - Surgical Site Infection, Vaginal Cuff Cellulitis | Enrolling by invitation | Baylor Research Institute | 900 | 2026-12-01 | 2026-10-22 | |
| WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole, Placebo Vaginal Capsule Metronidazole - Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | SPH Sine Pharmaceutical Laboratories Co., Ltd. | 150 | 2026-10-20 | 2026-10-22 |
| AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 1794 | 2026-10-01 | 2026-08-27 |
| Photobiomodulation With Blue LED in Recurrent Bacterial Vaginosis Metronidazole, Blue Light-Emitting Diode (LED) - Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 40 | 2026-09-30 | 2026-09-23 |
| Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV Vaginal estradiol tablets, Vaginal moisturizer - Menopausal Complaints, Vaginal Atrophy | Phase 4 | Not yet recruiting | Albert Einstein College of Medicine | 62 | 2026-09-01 | 2026-07-28 |
| MOTIF@FRESH: Modifying Organisms Transvaginally in Females @ FRESH Vaginal Microbiome Transplantation (VMT), oral metronidazole, Sterile saline solution - Recurrent Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | Douglas Kwon | 75 | 2026-09-01 | 2026-05-18 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| Improving Maternal and Child Health Through Point-of-care STI Testing Point-of-care STI tests, Standard of care STI testing - Treponema Pallidum Infection, Chlamydia Trachomatis Infection | Not applicable | Recruiting | Emory University | 756 | 2026-08-11 | 2026-08-19 |
| Photobiomodulation for Vaginal Dysfunctions: Home-Based vs Outpatient Treatment Blue LED Photobiomodulation - Genitourinary Syndrome of Menopause (GSM), Bacterial Vaginosis | Not applicable | Not yet recruiting | Patricia Lordelo | 150 | 2026-07-30 | 2026-07-13 |
| F-GYN for Vaginal Dryness and Vulvovaginal Atrophy F-GYN Non-Crosslinked Hyaluronic Acid Injectable Gel, Standard Non-Hormonal Symptomatic Care - Atrophic Vaginitis, Atrophic Vulvovaginitis | Not applicable | Recruiting | Biovico Sp. z o.o. | 130 | 2026-07-24 | 2026-10-01 |
| Efficacy and Safety of a Vaginal Ovule Medical Device for Bacterial Vaginosis and Candidal Vaginitis (ROVUL25). Class IIa vaginal medical device supplied as vaginal ovules, intended as an adjuvant in prevention of vaginal infections and symptoms., Placebo. - Bacterial Vaginosis, Candidal Vaginitis | Not applicable | Not yet recruiting | ROELMI HPC | 80 | 2026-07-09 | 2026-07-14 |
| Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence OCF001 Intravaginal Gel, Placebo Gel - Candidiasis, Vulvovaginal | Phase 2 | Recruiting | Sano Chemicals Inc | 36 | 2026-06-04 | 2026-06-15 |
| Large Algorithm Setting and Validation Study Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP - Bacterial Infections, Bacterial Infections and Mycoses | Recruiting | Nanopath, Inc | 1000 | 2026-06-03 | 2026-07-20 | |
| Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis Bioithas WOMAN® - Vulvovaginal Candidiasis (VVC) | Not applicable | Recruiting | Bioithas SL | 60 | 2026-05-25 | 2026-05-22 |
| Impact of Clinician-administered Vaginal Live Biotherapeutic Product LC106 - Bacterial Vaginosis | Early Phase 1 | Completed | Caroline Mitchell | 26 | 2026-04-28 | 2026-09-29 |
| The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study Vaginal lactoferrin, Usual care - Bacterial Vaginosis, Candida Vaginal | Not applicable | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 114 | 2026-04-16 | 2026-05-29 |
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota Samples collection (whole blood, urine, vaginal and cervical cells) - Sexual Transmitted Disease, Vaginosis, Bacterial | Recruiting | Centre National de la Recherche Scientifique, France | 300 | 2026-04-07 | 2026-04-09 | |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
Showing 20 of 435. Sign in to see all of them.
Vaginosis, Bacterial (235) · Candidiasis, Vulvovaginal (107) · Atrophic Vaginitis (44) · Trichomonas Vaginitis (22) · Candidiasis (21) · Vaginal Diseases (18) · Premature Birth (14) · Sexually Transmitted Diseases (14) · HIV Infections (13) · Vulvovaginitis (12) · Urinary Tract Infections (11) · Gonorrhea (10) · Vaginal Discharge (10) · Mycoses (9)
Female Urogenital Diseases and Pregnancy Complications (435) · Genital Diseases (435) · Female Urogenital Diseases (432) · Urogenital Diseases (431) · Genital Diseases, Female (430) · Vaginal Diseases (417) · Infections (342) · Bacterial Infections and Mycoses (326) · Bacterial Infections (236) · Vulvar Diseases (115) · Vulvitis (113) · Mycoses (109) · Vulvovaginitis (101) · Candidiasis (95)
Metronidazole (52) · Fluconazole (22) · Clindamycin (11) · Clotrimazole (11) · Estradiol (8) · Probiotics (8) · ibrexafungerp (8) · Dehydroepiandrosterone (6) · VT-1161 (6) · Estriol (5) · Tinidazole (5) · Vaginal Creams, Foams, and Jellies (5) · Azithromycin (4) · Benchmarking (4) · Estrogens, Conjugated (USP) (4)
National Institute of Allergy and Infectious Diseases (NIAID) (9) · Gedea Biotech AB (8) · Scynexis, Inc. (8) · Peking University Shenzhen Hospital (7) · University of Pittsburgh (7) · Assiut University (6) · EndoCeutics Inc. (6) · Starpharma Pty Ltd (6) · University of Alabama at Birmingham (6) · Medinova AG (5) · Skaraborg Hospital (4) · Stratpharma AG (4) · Vaginal Biome Science (4) · Bayer (3) · Carmel Medical Center (3)
United States (151) · China (27) · Canada (18) · France (15) · Israel (15) · Brazil (13) · Sweden (13) · Egypt (11) · Spain (11) · Germany (10) · India (10) · Italy (10) · South Africa (9) · United Kingdom (9) · Turkey (Türkiye) (8)
Shangrong Fan, M.D. (5) · David Angulo, MD (3) · David F Archer, MD (3) · Jeremy Paull, PhD (3) · Robert J Borgman, Ph.D. (3) · Sharon L Hillier, PhD (3) · Alena Jandourek, MD (2) · Andrea R Thurman, MD (2) · Caroline Mitchell, MD, MPH (2) · David F Archer, M.D. (2) · Harold C Wiesenfeld, MD, CM (2) · Jane Schwebke, MD (2) · Jeremy Paull, PhD. (2) · Jim Joffrion (2)
PMID 26972555, PMID 36396498, PMID 25968836, PMID 21854593, PMID 23985562, PMID 25734980, PMID 26291918, PMID 26517756, PMID 26597311, PMID 26634942, PMID 26731686, PMID 33207004, PMID 36255448, PMID 37431855, PMID 38319878, PMID 40709601, PMID 40970688, PMID 11166145, PMID 11463927, PMID 12762087, PMID 12861145, PMID 12954522, PMID 15028938, PMID 15458898, PMID 16303068, PMID 16458626, PMID 16647928, PMID 16648432, PMID 17054136, PMID 17128343, PMID 17413534, PMID 17666604, PMID 17972087, PMID 18489500, PMID 18532873, PMID 18698279, PMID 19220138, PMID 19252451, PMID 19321868, PMID 19389002, PMID 19424093, PMID 19436225, PMID 19436226, PMID 19553425, PMID 19616720, PMID 19936044, PMID 20027045, PMID 20370481, PMID 20428282, PMID 20459349
2014 (2), 2023 (2), 2008 (1), 2009 (1), 2017 (1), 2019 (1), 2025 (1), K23AG062400 (1), KL2RR025754 (1), P30AI027757 (1), R01AG102277 (1), R01AI045468 (1), R01AI058033 (1), R01AI170564 (1), R01HD077872 (1)